Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
Lehmann R et al. | Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. | 2004 | Am. J. Transplant. | pmid:15196070 |
Lemahieu W et al. | Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. | 2005 | Am. J. Transplant. | pmid:15888045 |
Axelrod D et al. | Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. | 2005 | Am. J. Transplant. | pmid:15888050 |
Reyes J et al. | Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). | 2005 | Am. J. Transplant. | pmid:15888051 |
Knoop C et al. | Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. | 2005 | Am. J. Transplant. | pmid:15888057 |
Kandaswamy R et al. | A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. | 2005 | Am. J. Transplant. | pmid:15888064 |
Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
Cosio FG and Larson TS | Cardiovascular disease after transplantation: do we know all of the variables? | 2003 | Am. J. Transplant. | pmid:12859523 |
de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
Latran M | Response to Klintmalm on the use of generic immunosuppression. | 2012 | Am. J. Transplant. | pmid:22176636 |
Krenzien F et al. | Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:27754593 |
O'Grady JG et al. | Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. | 2007 | Am. J. Transplant. | pmid:17109723 |
Böhmig GA et al. | Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. | 2007 | Am. J. Transplant. | pmid:17109725 |
Hirsch HH et al. | Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. | 2013 | Am. J. Transplant. | pmid:23137180 |
Mujtaba MA et al. | Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. | 2014 | Am. J. Transplant. | pmid:25179306 |
Alloway RR et al. | A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. | 2012 | Am. J. Transplant. | pmid:22759200 |
Wlodarczyk Z et al. | Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. | 2009 | Am. J. Transplant. | pmid:19681813 |
Chisholm-Burns MA et al. | Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681814 |
Schold JD and Kaplan B | AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681827 |
Troppmann C et al. | Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. | 2004 | Am. J. Transplant. | pmid:15023146 |
Pirenne J et al. | Tolerance of liver transplant patients to strenuous physical activity in high-altitude. | 2004 | Am. J. Transplant. | pmid:15023147 |
Heisel O et al. | New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. | 2004 | Am. J. Transplant. | pmid:15023151 |
Hardinger KL et al. | Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. | 2004 | Am. J. Transplant. | pmid:15023155 |
Suwelack B et al. | Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. | 2004 | Am. J. Transplant. | pmid:15023160 |
Madariaga ML et al. | Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. | 2015 | Am. J. Transplant. | pmid:25824550 |
Busque S et al. | Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | 2009 | Am. J. Transplant. | pmid:19660021 |
Lemahieu WP et al. | Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095503 |
Meier-Kriesche HU et al. | Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095509 |
Senior PA et al. | Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. | 2005 | Am. J. Transplant. | pmid:16095517 |
Padiyar A et al. | Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. | 2010 | Am. J. Transplant. | pmid:20055793 |
Hardinger KL et al. | BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. | 2010 | Am. J. Transplant. | pmid:20055811 |
Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
Borrows R et al. | Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. | 2006 | Am. J. Transplant. | pmid:16433766 |
Kohnle M et al. | Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. | 2006 | Am. J. Transplant. | pmid:16433776 |
Larson TS et al. | Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. | 2006 | Am. J. Transplant. | pmid:16468960 |
Vitko S et al. | Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. | 2006 | Am. J. Transplant. | pmid:16468962 |
Knechtle SJ et al. | Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. | 2009 | Am. J. Transplant. | pmid:19344431 |
Pallet N et al. | Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. | 2015 | Am. J. Transplant. | pmid:25588704 |
Min SI et al. | Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. | 2013 | Am. J. Transplant. | pmid:23734831 |
Bunnapradist S et al. | Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. | 2013 | Am. J. Transplant. | pmid:23279614 |
Ceschi A et al. | Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. | 2013 | Am. J. Transplant. | pmid:23279718 |
Shapiro R et al. | Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. | 2007 | Am. J. Transplant. | pmid:17908272 |
Rush D et al. | Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. | 2007 | Am. J. Transplant. | pmid:17908280 |
Kofler S et al. | Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. | 2009 | Am. J. Transplant. | pmid:19519820 |
Barbas AS et al. | Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. | 2013 | Am. J. Transplant. | pmid:23331705 |
Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
Fujishiro J et al. | Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. | 2010 | Am. J. Transplant. | pmid:20642681 |
Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |